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Introduction
The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a potent lung procarcinogen in laboratory animals, and a human carcinogen (Hecht et al., 1989; IARC monograph 89, 2007) . The carcinogenic effects of NNK depend on cytochrome P450 (P450)-mediated NNK α -hydroxylation at the methylene group or the methyl group, generating two distinct electrophilic intermediates, which can respectively methylate and pyridyloxobutylate DNA (Hecht, 1998) . The methylene hydroxylation and methyl hydroxylation pathways also produce 4-oxo-4-(3-pyridyl)-butanone (OPB) and 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB), respectively, which are used to represent activities of the respective α -hydroxylation pathways (Scheme 1). Multiple human and mouse P450s are active in the bioactivation of NNK in vitro, including human CYP1A, 2A, 2B, 2D, and 3A, and mouse CYP1A, 2A, and 2B enzymes (Smith et al., 1993; Hecht et al., 1998; Jalas et al., 2005) . On the other hand, NNK can be metabolized by P450 to form NNK-N-oxide, which results in detoxification (Castonguay et al., 1983) . NNK is also extensively reduced by carbonyl reductase in the liver, forming 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the major circulating metabolite of NNK. Both NNAL and JPET # 190173 5 induced lung tumors in mice (Ronai et al., 1993) and of smoking-related lung adenocarcinoma in humans (Ahrendt et al., 2001; Westra et al., 1993) .
We have demonstrated previously that, while hepatic P450-mediated NNK metabolism influences the bioavailability of NNK in the lung, metabolic activation of NNK in the target tissue (the lung) plays an essential role in NNK-induced lung carcinogenesis (Weng et al., 2007) .
The specific P450 enzyme(s) responsible for NNK bioactivation in the lung have not been identified. Human CYP2A13, known to be expressed selectively in the respiratory tract (Su et al., 2000) , displayed greater enzymatic efficiency in catalyzing both methyl and methylene α -hydroxylation of NNK than did any other P450 enzymes examined (Su et al., 2000; Jalas et al., 2005) . It has been proposed that CYP2A13 plays a critical role in the bioactivation of NNK, and in NNK-induced initiation of lung cancer, in human smokers.
There is also evidence suggesting that CYP2A5, the ortholog of human CYP2A13 in mice, is essential for NNK bioactivation and tumorigenesis in the mouse lung. NNK readily induces lung adenocarcinoma following a single intraperitoneal injection of the carcinogen to mice (Hecht et al., 1989) . CYP2A5, which is expressed in the lung, as well as in liver, kidney, and nasal mucosa (Su et al., 1996) , is efficient in the bioactivation of NNK, as indicated by in vitro studies with recombinant CYP2A5 (Felicia et al., 2000; Jalas et al., 2003) . Furthermore, JPET # 190173 6 In the present study, we have directly determined the role of CYP2A5 in NNK bioactivation, both in vitro and in vivo, by comparing kinetic parameters of microsomal NNK metabolism and tissue levels of O 6 -mG between wild-type (WT) and Cyp2a5-null mice. The
Cyp2a5-null mouse model, produced through germline deletion of the last Cyp2a5 coding exon, has been used successfully in studies on the role of CYP2A5 in the clearance of nicotine and cotinine (Zhou et al., 2010) and the bioactivation of nasal toxicants 2,6-dichlorobenzonitrile (Xie et al., 2010) and methimazole (Xie et al., 2011) . Here, we present evidence that CYP2A5 is the low-Km enzyme for NNK bioactivation in mouse lung, and that P450s other than CYP2A5
probably also contribute to NNK-induced lung tumorigenesis in mice.
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-methyl-deoxyguanosine and O 6 -trideuteriomethyldeoxyguanosine were the same as described previously (Weng et al., 2007) . All solvents (acetonitrile, methanol, and water) were of high-performance liquid chromatography (LC) grade (ThermoFisher Scientific, Waltham, MA).
Determination of Catalytic Activity. Lung and liver microsomes were prepared as described (Ding and Coon, 1990) . Protein concentration was determined by the bicinchoninic acid method (Pierce Chemical, Rockford, IL) with bovine serum albumin as the standard. For identification of microsomal NNK metabolites, assay mixtures contained 100 mM potassium phosphate buffer, pH 7.4, 10 µM NNK, 0.5 mg/ml liver or lung microsomal protein, 0 or 5 mM sodium bisulfite (as a trapping agent for OPB; Peterson et al., 1991b) , and 1.0 mM NADPH, in a final volume of 0.2 ml. Reactions were carried out at 37°C for 30 min, and were terminated by the addition of 0.2 ml of acetonitrile. NADPH was omitted in negative control incubations. The apparent Km and Vmax values were determined using a broad range of NNK concentrations (0.5, 1, 2.5, 10, 25, 50, 100, 200 µM), with 0.25 mg/ml liver or lung microsomal protein from 2-month-old female WT A/J or B6 mice, or Cyp2a5-null mice (on B6 genetic background); the This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 19, 2012 as DOI: 10.1124 at ASPET Journals on July 6, 2017 jpet.aspetjournals.org Downloaded from reactions were carried out for 10 (for liver) or 30 (for lung) min, at 37°C, conditions under which the rates of product formation were linear with time, in the presence of 5 mM sodium bisulfite and 1 mM NADPH.
To determine the effects of 8-MOP on NNK bioactivation, 8-MOP (0, 0.5, or 2.5 µM)
was first added (in 2 µl 50% methanol in H 2 O) to "preincubation" mixtures consisting of 100 mM potassium phosphate buffer, pH 7.4, microsomal proteins (0.25 mg/ml) from 2-month-old
Cyp2a5-null female mice, and 1 mM NADPH, in a total volume of 0.2 ml, and the mixture was incubated at 30°C for 20 min. NNK and sodium bisulfite were then added to the preincubation mixture, to final concentrations of 5 µM and 5 mM, respectively, and a final volume of 0.22 ml, and the incubation was continued at 30° C for another 10 (for liver) or 30 (for lung ) min. A lower temperature (30 o C) was used, according to a published protocol (von Weymarn et al., 2005) , in order to minimize NADPH-dependent activity losses in the control samples (with 0 µM
8-MOP).
For all reactions, internal standards (500 pg each of D 4 -HPB and D 4 -NNK) were added after the microsomal reactions were terminated with acetonitrile. The resultant mixtures were spun to remove precipitated protein; the supernatant was dried with nitrogen and then reconstituted in 50 µl of 50% (v/v) acetonitrile and 0.05% (w/v) formic acid in water for liquid JPET # 190173 9 points (10 min to 4 h) after the injection. The samples were centrifuged at 1000g, for 5 min, at 4°C, for preparation of plasma. For determination of tissue levels of O 6 -mG DNA adduct, liver and lung were obtained at 4 h after NNK injection (at 20 or 100 mg/kg). For studies on in vivo inhibition of NNK clearance and bioactivation by 8-MOP, 2-month-old Cyp2a5-null female mice were pretreated via oral gavage with 8-MOP at 0 (vehicle control), 12.5, or 50 mg/kg in 0.2 ml corn oil, daily for 3 days, essentially as described previously (Takeuchi et al., 2003) . One hour after the final dose of 8-MOP, NNK was given (at 100 mg/kg, i.p.) and the blood and tissue samples were collected as described above. Plasma and tissue samples were processed for LC-MS analysis of NNK/NNAL and O 6 -mG, respectively, essentially as described earlier (Supplementary Materials in Weng et al., 2007) .
LC-MS Analytical Methods.
A LC-MS system composed of an Agilent 1200 Series high performance LC and an ABI 4000 Q-Trap mass spectrometer (Applied Biosystems, Foster City, CA) was used. Analytes were resolved using a 5-µm Gemini C18 column (100 x 2.0 mm, Phenomenex, Torrance, CA). The mass spectrometer was operated in a positive ion mode with an electrospay ionization source. The parameters for the chamber were as follows: curtain gas, 30 psi; heated nebulizer temperature, 350°C; ion spray voltage, 4500 V; nebulizer gas, 50 psi; turbo gas, 50 psi, declustering potential, 50 V; and entrance potential, 10 V.
For identification of NNK metabolites, the mobile phase consisted of solvent A (0.05% formic acid in water) and solvent B (0.05% formic acid in acetonitrile). Samples were eluted, at a flow rate of 0.3 ml/min, with 100% A for 2 min, followed by linear increases from 0% B to 100%
B between 2 and 15 min, and then 100% B for a further 2.5 min. The mass spectrometer was set for the information-dependent acquisition scan mode, using multiple ion monitoring-dependent .2, and 6.7 min, respectively; under neutral condition, the retention times for HPB, NNK-Noxide, and NNK were 6.5, 6.2, and 7.2 min, respectively, whereas OPB-bisulfite was unstable (as Vmax values for the formation of OPB and HPB by liver and lung microsomes from B6 and A/J female mice were determined (Supplemental Table 1 ); the kinetic parameters determined, which were nearly identical between A/J and B6 mice, were comparable to reported values (Peterson et al., 1991b; Nunes et al., 1998; Jalas et al., 2003) .
Role of CYP2A5 in NNK Bioactivation in vitro.
The contribution of CYP2A5 to NNK bioactivation in liver and lung microsomal reactions was determined by comparing activities between Cyp2a5-null mice (on B6 genetic background) and WT B6 mice. Female mice were studied, given the preferred use of female mice in NNK lung tumorigenesis bioassays (Hecht et al., 1989) ; in vitro NNK bioactivation by mouse lung and liver microsomes did not display obvious sex difference in the WT or Cyp2a5-null mice (data not shown). As shown in To determine whether the loss of CYP2A5 in the Cyp2a5-null mice impact systemic elimination of NNK and its major circulating metabolite NNAL, plasma levels of NNK and NNAL were measured in WT and Cyp2a5-null mice, following NNK administration at either 20 ( Fig. 2A, B) This article has not been copyedited and formatted. The final version may differ from this version. Following NNK treatment at 100 mg/kg, a standard dose used in lung tumorigenesis bioassays in mice (e.g., Weng et al., 2007) , the levels of O 6 -mG were found to be ~20% lower in the lungs of Cyp2a5-null than in the lungs of WT mice (Table 2) . At a lower (20 mg/kg) NNK dose, the O 6 -mG levels were >40% lower in the lungs of Cyp2a5-null than in the lungs of WT mice. These results indicate that CYP2A5 contributed to NNK bioactivation in the mouse lung in vivo, and that CYP2A5's contribution was much greater at the lower NNK dose tested, consistent with the results of in vitro studies showing that CYP2A5 is a low-Km enzyme for catalyzing the formation of OPB in lung microsomes (Table 1) .
In contrast to the situation in the lung, the O 6 -mG levels in the livers of WT and Cyp2a5-null mice were not different at 4 h after NNK treatment, at either dose. Thus, under the dosing conditions used, CYP2A5 does not contribute substantially to NNK bioactivation in the liver in vivo, despite the in vitro data showing that CYP2A5 is the low-Km enzyme for catalyzing the This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 19, 2012 as DOI: 10.1124 at ASPET Journals on July 6, 2017 jpet.aspetjournals.org Downloaded from formation of both OPB and HPB in liver microsomes (Table 1) . This result is also consistent with the lack of an impact of the CYP2A5 loss on NNK systemic clearance in our pharmacokinetics study (Fig. 2) . remaining NNK bioactivation activity in the lungs of the Cyp2a5-null mice, we further tested whether the remaining bioactivation activities are also inhibited by 8-MOP, with NNK given at 100 mg/kg, as was in the original study (Takeuchi et al., 2003) . Contrary to the lack of effects of CYP2A5 loss on NNK clearance (Fig. 2) , the rates of NNK clearance were decreased in the Cyp2a5-null mice by pretreatment of mice with 8-MOP at 50 mg/kg, as indicated by the increased plasma NNK and NNAL levels at various time points after NNK administration (Fig.   3 ). However, despite the increased NNK bioavailability, the levels of O 6 -mG in the lungs and livers were decreased, by ~70%, in the Cyp2a5-null mice pretreated with 8-MOP at 50 mg/kg (Table 3 ). In Cyp2a5-null mice pretreated with 8-MOP at the lower (12.5 mg/kg) dose, which did not result in a change in NNK clearance (Fig. 3) , the levels of O 6 -mG were also reduced, by 40%
Effects
and 30%, in the livers and lungs, respectively (Table 3) The effects of 8-MOP on NNK bioactivation were further investigated in vitro, using lung and liver microsomes from Cyp2a5-null mice, and using a 8-MOP preincubation scheme to mimic the pretreatment paradigm used in vivo, given the potential role of 8-MOP as mechanismbased, competitive, and non-competitive P450 inhibitors (Visoni et al., 2008) . A pilot study (not shown) indicated that a 20-min preincubation with 8-MOP led to maximal inhibition of the activities toward NNK in either lung or liver microsomes from Cyp2a5-null mice. As shown in Figure 4 , the formation of both OPB and HPB was inhibited, in a 8-MOP dose-dependent manner.
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Discussion
The present study was designed to test the hypothesis that mouse CYP2A5 plays an essential role in NNK bioactivation in mouse lung, by comparing kinetic parameters of microsomal NNK metabolism and tissue levels of O 6 -mG between WT and Cyp2a5-null mice.
Recombinant CYP2A5 is very efficient in the bioactivation of NNK, producing both OPB and HPB (Felicia et al., 2000; Jalas et al., 2003) . In the Cyp2a5-null mouse, the expression of CYP2A5, which is abundant in liver, lung and olfactory mucosa from WT mice, was abolished, and there was no compensatory change in the expression of other biotransformation enzymes examined, including multiple P450s and Phase II enzymes (Zhou et al., 2010; 2011) . The suitability of the mouse model for studying the specific role of CYP2A5 in NNK bioactivation in vivo was further confirmed by the finding that the loss of CYP2A5 expression does not alter the rate of systemic clearance of NNK or its major circulating metabolite NNAL, a result indicating that the lungs of WT and Cyp2a5-null mice were exposed to similar levels of NNK and NNAL following the NNK treatment. Therefore, differences between the two mouse strains in the levels of lung DNA adducts detected were not because of differences in substrate (NNK) availability.
In that connection, although CYP2A5 was abolished in all tissues of the Cyp2a5-null mice, the impact of the CYP2A5 loss on DNA adduct formation in the lung can be attributed to the contribution of lung CYP2A5, given our previous finding in a study on a lung-specific Cpr-null mouse that NNK-induced lung DNA adduct (O 6 -mG) formation and tumorigenesis depends on target-tissue bioactivation by pulmonary P450 enzymes.
NNK metabolism was analyzed previously using radiometric LC assays, with use of Our previous studies using a liver-specific Cpr-null mouse model showed that hepatic P450 enzymes are protective against NNK-induced lung tumorigenesis (Weng et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. NNK can be detoxified via formation of NNK-N-oxide; although the specific mouse P450 enzymes responsible for NNK N-oxide formation have not been identified, rat CYP2B1 and CYP2C6 have been found to be active in NNK N-oxide formation (for a review see Jalas et al., 2005) . Notably, our present data showed that the loss of CYP2A5 did not impact the rates of NNK-N-oxide formation in either liver or lung microcosms, indicating that CYP2A5 is not involved in this detoxification pathway.
The remaining activity of NNK bioactivation in the lung of Cyp2a5-null mice, which is rather high, may reflect the contributions by other P450 enzymes; members of several CYP subfamilies have been reported to be active in NNK bioactivation, including CYP1A, CYP2B, and CYP2F (Smith et al., 1993; Hecht et al., 1998) . In addition, CYP2A4, although expressed in the lung at levels much lower than that of CYP2A5 (Su et al., 1996) , displayed activity for NNK bioactivation (Jalas et al., 2005) . In that connection, it is notable that, although CYP2A5 is a low-Km enzyme in the formation of HPB (Hecht et al., 1998) , the contribution of CYP2A5 to the formation of HPB in mouse lung microsomes was negligible in our study. Thus, other low-Km enzymes, which are likely more abundant than CYP2A5 is in mouse lung microsomes, may play a more pivotal role in catalyzing the formation of HPB. Preliminary studies comparing lung microsomes from WT and Cyp2f2-null mice (Li et al., 2011) seem to indicate that mouse CYP2F2, which is highly abundant in lung microsomes, is another low-Km enzymes for the formation of HPB (Zhou et al., unpublished).
Our finding that remaining NNK-bioactivation activities in the Cyp2a5-null mice could be inhibited by 8-MOP, a P450 inhibitor utilized previously to demonstrate the role of CYP2A5
in NNK-induced lung tumorigenesis (Miyazaki et al., 2005) , further supports the notion that P450 enzymes other than CYP2A5 also contribute to NNK-induced lung tumorigenesis in mice.
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The ability of 8-MOP to act as a mechanism-based inhibitor of CYP2A enzymes has been well documented (Koenigs et al., 1997 and von Weymarn et al., 2005) ; 8-MOP was also found to inhibit mouse CYP2A5 through additional (competitive and non-competitive) mechanisms (Visoni et al., 2008) . However, the specificity of inhibition of CYP2A enzymes by 8-MOP is not absolute, particularly at high 8-MOP concentration or doses; e.g., 8-MOP inhibited mouse hepatic microsomal metabolism of carbon tetrachloride, a CYP2E1 substrate, and caffeine, a CYP1A2 substrate, both in vitro and in vivo (Labbe et al., 1987; Apseloff et al., 1991) .
Additional studies to directly demonstrate the role of CYP2A5, as well as other P450
enzymes, including CYP2F2 and CYP2B, in NNK-induced lung tumorigenesis are warranted. In that regard, the current Cyp2a5-null mouse is on the B6 genetic background, which is resistant to lung tumorigenesis. However, we have confirmed that there is no strain difference in NNK bioactivation in liver and lung microsomes between B6 and A/J mice; the latter is an established mouse strain for studies of NNK-induced lung tumorigenesis. Therefore, future studies for the role of CYP2A5 in NNK-induced lung tumorigenesis can be performed using Cyp2a5-null mice on the A/J background. In that connection, a recent study of a mouse model with targeted deletion of Akt, a putative oncogene closely linked to the Cyp2a locus on mouse chromosome 7, has already yielded indirect evidence that genetic variations in CYP2A5 can impact susceptibility to NNK-induced lung tumorigenesis in mice (Hollander et al., 2011) .
Our demonstration of the role of CYP2A5 in NNK bioactivation in the mouse lung in vivo lends further support to the idea that human CYP2A13, which is even more efficient than mouse CYP2A5 is in NNK bioactivation (Jalas et al., 2005) , is a susceptibility gene for NNKinduced lung carcinogenesis in humans. CYP2A13 protein is expressed in human lung (Zhu et al., 2006; Zhang et al., 2007) . Levels of CYP2A13 protein expression correlated with rates of lung In conclusion, we proved that CYP2A5 is the low-Km enzyme for NNK bioactivation in the mouse lung, although P450 enzymes other than CYP2A5 also contribute. Our findings lay important foundation for further demonstration of the ability of human CYP2A13 to catalyze 
Cyp2a5-null mice
Two-month-old, female Cyp2a5-null mice were pretreated with 8-MOP (at 0, 12.5, or 50 mg/kg, p.o.) in 0.2 ml corn oil, once daily for three consecutive days. One hour after the final injection of 8-MOP, NNK was given at a dose of 100 mg/kg (i.p.), and tissue levels of O 6 -mG and total guanine were determined at 4 h after the NNK injection. Data represent means ± S.D.
(n = 4). 
